

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Withdrawn/Currently Amended). A method for inhibiting aggregation of  $\beta$ -amyloid in a subject or disaggregating aggregated  $\beta$ -amyloid in a subject, comprising administering to a subject in need thereof an effective amount of ~~a filamentous bacteriophage which displays an antibody or epitope binding fragment thereof, wherein said antibody and epitope binding fragment thereof bind to an epitope of  $\beta$ -amyloid so as to inhibit aggregation of  $\beta$ -amyloid in said subject and/or to cause disaggregation of a  $\beta$ -amyloid aggregate in said subject~~ in accordance with claim 30.

2 (Withdrawn). The method of claim 1, wherein said epitope of  $\beta$ -amyloid comprises the amino acid sequence of SEQ ID NO:1.

3 (Withdrawn). The method of claim 2, wherein said epitope is contained in a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:21, and SEQ ID NO:22.

4 (Withdrawn). The method of claim 1, wherein said antibody or epitope binding fragment thereof is displayed on said bacteriophage via coat glycoprotein VIII.

5 (Withdrawn). The method of claim 1, wherein said  $\beta$ -amyloid is selected from the group consisting of A $\beta$ 39, A $\beta$ 40, A $\beta$ 41, A $\beta$ 42 and A $\beta$ 43.

6 (Withdrawn). The method of claim 1, wherein said administering is to the olfactory system of said subject.

7 (Currently Amended). A pharmaceutical composition comprising a ~~pharmaceutically acceptable carrier and, as an active ingredient, a~~ filamentous bacteriophage, wherein said filamentous bacteriophage consists of a filamentous bacteriophage that ~~which~~ displays an antibody or epitope binding fragment thereof, wherein said antibody and epitope binding fragment thereof bind to an epitope of  $\beta$ -amyloid so as to inhibit aggregation of  $\beta$ -amyloid in a subject and/or to cause disaggregation of a  $\beta$ -amyloid aggregate in a subject, wherein said filamentous bacteriophage displaying said antibody or epitope binding fragment is an active ingredient of the composition and the composition further comprises a pharmaceutically acceptable carrier.

8 (Original). The pharmaceutical composition of claim 7, wherein said epitope of  $\beta$ -amyloid comprises the amino acid sequence of SEQ ID NO:1.

9 (Original). The pharmaceutical composition of claim 8, wherein said antibody or epitope binding fragment

thereof is displayed on said bacteriophage via coat glycoprotein VIII.

10 (Original). The pharmaceutical composition of claim 8, wherein said epitope is contained in a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:21, and SEQ ID NO:22.

11 (Original). The pharmaceutical composition of claim 7, wherein said  $\beta$ -amyloid is selected from the group consisting of A $\beta$ 39, A $\beta$ 40, A $\beta$ 41, A $\beta$ 42 and A $\beta$ 43.

12-24 (Cancelled)

25 (Currently Amended). A composition, comprising:  
(a) a carrier and a filamentous bacteriophage,  
wherein said filamentous bacteriophage consists of a  
filamentous bacteriophage that displays an antibody or epitope binding fragment thereof, wherein said antibody and epitope binding fragment thereof bind to an epitope of  $\beta$ -amyloid so as to inhibit aggregation of  $\beta$ -amyloid or cause disaggregation of a  $\beta$ -amyloid aggregate; and  
(b) a carrier.

26 (Previously Presented). The composition of claim 25, wherein said epitope of  $\beta$ -amyloid comprises the amino acid sequence of SEQ ID NO:1.

27 (Previously Presented). The composition of claim 26, wherein said antibody or epitope binding fragment thereof is displayed on said bacteriophage via coat glycoprotein VIII.

28 (Previously Presented). The composition of claim 26, wherein said epitope is contained in a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:21, and SEQ ID NO:22.

29 (Previously Presented). The composition of claim 25, wherein said  $\beta$ -amyloid is selected from the group consisting of A $\beta$ 39, A $\beta$ 40, A $\beta$ 41, A $\beta$ 42 and A $\beta$ 43.

30 (Currently Amended). ~~A filamentous~~Filamentous bacteriophage consisting of filamentous bacteriophage that displays an antibody or epitope binding fragment thereof, wherein said antibody and epitope binding fragment thereof bind to an epitope of  $\beta$ -amyloid so as to inhibit aggregation of  $\beta$ -amyloid or cause disaggregation of a  $\beta$ -amyloid aggregate.

31 (Previously Presented). The filamentous bacteriophage of claim 30, wherein said epitope of  $\beta$ -amyloid comprises the amino acid sequence of SEQ ID NO:1.

32 (Previously Presented). The filamentous bacteriophage of claim 31, wherein said antibody or epitope binding fragment thereof is displayed on said bacteriophage via coat glycoprotein VIII.

33 (Previously Presented). The filamentous bacteriophage of claim 31, wherein said epitope is contained in a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:21, and SEQ ID NO:22.

34 (Previously Presented). The filamentous bacteriophage of claim 30, wherein said  $\beta$ -amyloid is selected from the group consisting of A $\beta$ 39, A $\beta$ 40, A $\beta$ 41, A $\beta$ 42 and A $\beta$ 43.